News | May 15, 2023
Medico Remedies to foray into ointment manufacturing segment
The facility will have a capacity to manufacture upto 3 million tubes monthly
The facility will have a capacity to manufacture upto 3 million tubes monthly
The additional $50 million will go towards venture capital firms that specialize in near- and long-term healthcare solutions for patients in low- and middle-income countries
Acquisition of XinThera provides Gilead with precision small molecules focused on PARP1 and MK2 Inhibitors
‘Fibrotic disease’ is a term that covers a range of diseases characterized by uncontrolled and progressive fibrosis,
Both the companies intend to facilitate faster clinical trial enrollment and provide patients with access to novel medications
APP13007 is a novel aqueous nanosuspension formulation for the treatment of inflammation and pain following ocular surgery
Nous-209 has been developed using the Nouscom's viral vector platform
Indoco expects this change in compliance status to pave the way for approvals of ANDAs submitted from this site.
The committee voted that FDA should restrict use of LYNPARZA plus abi/pred to these BRCAm mCRPC patients
The YP-P10 pre-clinical head-to-head study, jointly conducted by five people including Dr. Kyungho Park of Naason Science
Subscribe To Our Newsletter & Stay Updated
